ReviewIndian pediatrics2025
An Update on WHO Recommendations on Childhood Pneumonia and Diarrhea (2024).
Review in Indian pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiology, bacterial coinfection risk factors, and inflammatory markers in children with RSV, AdV, and hMPV pneumonia in Zunyi, China.BMC infectious diseases · 2026Article
- The Role of Zinc in Pediatric Respiratory Infections: Evidence from Clinical Trials and Real-World Studies.Nutrients · 2026Review
- Zinc gluconate ameliorates antibiotics/PGN-induced intestinal injury via modulating the gut barrier, macrophages immunity and gut microbiota.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2024 World Health Organization (WHO) guidelines present important updates in the management of pneumonia and diarrhea in children. There is a conditional recommendation of a reduced zinc dose-5 mg daily for up to 14 days-for children up to 10 years of age with acute watery or persistent diarrhea, intended to lower the risk of vomiting while preserving therapeutic efficacy. Antibiotic use is discouraged for acute watery diarrhea, except in cases with visible blood in stool, where ciprofloxacin remains the first-line treatment. Probiotics are not recommended due to low-certainty evidence and concerns about feasibility. Oral amoxicillin continues to the first-line treatment for children aged 2-59 months with fast breathing or chest indrawing. These cases can be managed effectively even in community settings. Substantial knowledge gaps persist regarding the best antibiotic regimens and clinical diagnostic strategies for pneumonia in children aged 5-9 years.
Indexed as
Identifiers
40839064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.